CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality
Menée à partir des données de sept études conduites entre 2013 et 2017 et portant sur 4 200 patientes atteintes d'un cancer du sein HR+ HER2- de stade avancé ou métastatique, cette étude analyse l'efficacité, du point de vue de la survie sans progression, de l'ajout d'un inhibiteur anti-CDK4/6 à une thérapie endocrinienne (durée médiane de suivi : 19,7 mois)
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have been widely incorporated into the care of women with metastatic hormone receptor-positive, HER2-negative breast cancer. In The Lancet Oncology, Jennifer Gao and colleagues from the US Food and Drug Administration (FDA) pooled individual patient data from all seven phase 3 randomised trials (including a total of 4200 patients) of CDK4/6 inhibitors in combination with endocrine therapy that were submitted to the FDA in support of marketing applications for these drugs. Their pooled efficacy analysis was done in several less common subgroups of patients with breast cancer: progesterone receptor-negative disease; patients with a disease-free interval up to 12 months; de-novo metastatic, lobular histology, and bone-only disease; those with visceral metastases; and patients aged 40 years or younger.
The Lancet Oncology 2019